Harbin Medisan Pharmaceutical Co (SZSE:002900) Additional Paid-In Capital : ¥0 Mil(As of Mar. 2024)

View and export this data going back to 2017. Start your Free Trial

What is Harbin Medisan Pharmaceutical Co Additional Paid-In Capital?

Harbin Medisan Pharmaceutical Co's quarterly additional paid-in capital increased from Sep. 2023 (¥0 Mil) to Dec. 2023 (¥1,037 Mil) but then stayed the same from Dec. 2023 (¥1,037 Mil) to Mar. 2024 (¥0 Mil).

Harbin Medisan Pharmaceutical Co's annual additional paid-in capital stayed the same from Dec. 2021 (¥1,039 Mil) to Dec. 2022 (¥1,039 Mil) but then declined from Dec. 2022 (¥1,039 Mil) to Dec. 2023 (¥1,037 Mil).

Harbin Medisan Pharmaceutical Co Additional Paid-In Capital Historical Data

The historical data trend for Harbin Medisan Pharmaceutical Co's Additional Paid-In Capital can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Harbin Medisan Pharmaceutical Co Additional Paid-In Capital Chart

Harbin Medisan Pharmaceutical Co Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Additional Paid-In Capital

Get a 7-Day Free Trial

1,038.69

1,037.21

Harbin Medisan Pharmaceutical Co Quarterly Data
	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24
Additional Paid-In Capital	Get a 7-Day Free Trial															-	1,038.23	-	1,037.21	-

Harbin Medisan Pharmaceutical Co Additional Paid-In Capital Calculation

Capital that a company raises in a financing round in excess of the capital's par value. The account represents the excess paid by an investor over the par-value price of a stock issue. Additional paid-in-capital can arise from issuing either preferred or common stock.

Additional Paid-In Capital is calculated as

Additional Paid-In Capital

(Issue Price

Par Value)

Shares Outstanding (Diluted Average)

Harbin Medisan Pharmaceutical Co Additional Paid-In Capital Related Terms

Thank you for viewing the detailed overview of Harbin Medisan Pharmaceutical Co's Additional Paid-In Capital provided by GuruFocus.com. Please click on the following links to see related term pages.

Harbin Medisan Pharmaceutical Co (SZSE:002900) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Harbin Medisan Pharmaceutical Co Ltd (SZSE:002900) » Definitions » Additional Paid-In Capital

Traded in Other Exchanges

N/A

Address

Beijing Road, Limin Development Zone, Heilongjiang Province, Harbin, CHN, 150025

Website

http://www.medisan.com.cn

Harbin Medisan Pharmaceutical Co Ltd is the pharmaceutical manufacturing company. It is engaged in the research, development, manufacturing and sales of chemical preparations. The main products are oxiracetam injection, mirtazapine tablets, valsartan dispersible tablets, injection brain drugs such as protein hydrolysate, glucose injection and sodium chloride injection. The company is also involved in research, development, production and sales of medical devices.

Executives

Fan Qing Ji	Executives
Zhao Qing Fu	Directors, Directors, and Executives
Liang Yan Fei	Directors, executives
Yao Fa Xiang	Executives
Wang Ming Xin	Executives

Harbin Medisan Pharmaceutical Co (SZSE:002900) Headlines

No Headlines